Cargando…

GSK-J4, a Specific Histone Lysine Demethylase 6A Inhibitor, Ameliorates Lipotoxicity to Cardiomyocytes via Preserving H3K27 Methylation and Reducing Ferroptosis

Changes in modern lifestyle provoke a series of metabolic stresses such as hyperlipidemia. Excessive free fatty acids induce cardiomyocyte metabolic reprogramming and rearrangement of the lipid content of cardiomyocyte and promote oxidative stress. As a newly defined lipid peroxidation-related cell...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Kai, Liu, Xiang, Wen, Bin, Liu, Yazhou, Zhang, Wei, Hu, Xiaolin, Chen, Ling, Hang, Weijian, Chen, Juan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9200982/
https://www.ncbi.nlm.nih.gov/pubmed/35722096
http://dx.doi.org/10.3389/fcvm.2022.907747
_version_ 1784728185900892160
author Xu, Kai
Liu, Xiang
Wen, Bin
Liu, Yazhou
Zhang, Wei
Hu, Xiaolin
Chen, Ling
Hang, Weijian
Chen, Juan
author_facet Xu, Kai
Liu, Xiang
Wen, Bin
Liu, Yazhou
Zhang, Wei
Hu, Xiaolin
Chen, Ling
Hang, Weijian
Chen, Juan
author_sort Xu, Kai
collection PubMed
description Changes in modern lifestyle provoke a series of metabolic stresses such as hyperlipidemia. Excessive free fatty acids induce cardiomyocyte metabolic reprogramming and rearrangement of the lipid content of cardiomyocyte and promote oxidative stress. As a newly defined lipid peroxidation-related cell death pathway, the role of ferroptosis in metabolic stress-induced cardiomyocyte injury is poorly revealed. Our work indicates that GSK-J4, a histone lysine demethylase 6A/6B dual inhibitor, can alleviate palmitic acid (PA)-induced hypersensitivity to ferroptosis by suppressing H3K27 demethylation. Mechanistically, PA stimulation reduces the H3K27me3 level and hence promotes the expression of ACSL4, a key lipid modulator of ferroptosis. GSK-J4 pretreatment significantly preserves the H3K27me3 level and reduces the ACSL4 level. GSK-J4 also reduces reactive oxygen species to alleviate oxidative stress, which further decreases lipid peroxidation. Taken together, our data suggest that cardiomyocyte undergoes epigenetic reprogramming under metabolic challenges, rearranging lipid content, and sensitizing to ferroptosis. GSK-J4 can be a potential drug for treating hyperlipidemia-induced cardiomyocyte injury by targeting epigenetic modulations.
format Online
Article
Text
id pubmed-9200982
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-92009822022-06-17 GSK-J4, a Specific Histone Lysine Demethylase 6A Inhibitor, Ameliorates Lipotoxicity to Cardiomyocytes via Preserving H3K27 Methylation and Reducing Ferroptosis Xu, Kai Liu, Xiang Wen, Bin Liu, Yazhou Zhang, Wei Hu, Xiaolin Chen, Ling Hang, Weijian Chen, Juan Front Cardiovasc Med Cardiovascular Medicine Changes in modern lifestyle provoke a series of metabolic stresses such as hyperlipidemia. Excessive free fatty acids induce cardiomyocyte metabolic reprogramming and rearrangement of the lipid content of cardiomyocyte and promote oxidative stress. As a newly defined lipid peroxidation-related cell death pathway, the role of ferroptosis in metabolic stress-induced cardiomyocyte injury is poorly revealed. Our work indicates that GSK-J4, a histone lysine demethylase 6A/6B dual inhibitor, can alleviate palmitic acid (PA)-induced hypersensitivity to ferroptosis by suppressing H3K27 demethylation. Mechanistically, PA stimulation reduces the H3K27me3 level and hence promotes the expression of ACSL4, a key lipid modulator of ferroptosis. GSK-J4 pretreatment significantly preserves the H3K27me3 level and reduces the ACSL4 level. GSK-J4 also reduces reactive oxygen species to alleviate oxidative stress, which further decreases lipid peroxidation. Taken together, our data suggest that cardiomyocyte undergoes epigenetic reprogramming under metabolic challenges, rearranging lipid content, and sensitizing to ferroptosis. GSK-J4 can be a potential drug for treating hyperlipidemia-induced cardiomyocyte injury by targeting epigenetic modulations. Frontiers Media S.A. 2022-06-02 /pmc/articles/PMC9200982/ /pubmed/35722096 http://dx.doi.org/10.3389/fcvm.2022.907747 Text en Copyright © 2022 Xu, Liu, Wen, Liu, Zhang, Hu, Chen, Hang and Chen. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cardiovascular Medicine
Xu, Kai
Liu, Xiang
Wen, Bin
Liu, Yazhou
Zhang, Wei
Hu, Xiaolin
Chen, Ling
Hang, Weijian
Chen, Juan
GSK-J4, a Specific Histone Lysine Demethylase 6A Inhibitor, Ameliorates Lipotoxicity to Cardiomyocytes via Preserving H3K27 Methylation and Reducing Ferroptosis
title GSK-J4, a Specific Histone Lysine Demethylase 6A Inhibitor, Ameliorates Lipotoxicity to Cardiomyocytes via Preserving H3K27 Methylation and Reducing Ferroptosis
title_full GSK-J4, a Specific Histone Lysine Demethylase 6A Inhibitor, Ameliorates Lipotoxicity to Cardiomyocytes via Preserving H3K27 Methylation and Reducing Ferroptosis
title_fullStr GSK-J4, a Specific Histone Lysine Demethylase 6A Inhibitor, Ameliorates Lipotoxicity to Cardiomyocytes via Preserving H3K27 Methylation and Reducing Ferroptosis
title_full_unstemmed GSK-J4, a Specific Histone Lysine Demethylase 6A Inhibitor, Ameliorates Lipotoxicity to Cardiomyocytes via Preserving H3K27 Methylation and Reducing Ferroptosis
title_short GSK-J4, a Specific Histone Lysine Demethylase 6A Inhibitor, Ameliorates Lipotoxicity to Cardiomyocytes via Preserving H3K27 Methylation and Reducing Ferroptosis
title_sort gsk-j4, a specific histone lysine demethylase 6a inhibitor, ameliorates lipotoxicity to cardiomyocytes via preserving h3k27 methylation and reducing ferroptosis
topic Cardiovascular Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9200982/
https://www.ncbi.nlm.nih.gov/pubmed/35722096
http://dx.doi.org/10.3389/fcvm.2022.907747
work_keys_str_mv AT xukai gskj4aspecifichistonelysinedemethylase6ainhibitorameliorateslipotoxicitytocardiomyocytesviapreservingh3k27methylationandreducingferroptosis
AT liuxiang gskj4aspecifichistonelysinedemethylase6ainhibitorameliorateslipotoxicitytocardiomyocytesviapreservingh3k27methylationandreducingferroptosis
AT wenbin gskj4aspecifichistonelysinedemethylase6ainhibitorameliorateslipotoxicitytocardiomyocytesviapreservingh3k27methylationandreducingferroptosis
AT liuyazhou gskj4aspecifichistonelysinedemethylase6ainhibitorameliorateslipotoxicitytocardiomyocytesviapreservingh3k27methylationandreducingferroptosis
AT zhangwei gskj4aspecifichistonelysinedemethylase6ainhibitorameliorateslipotoxicitytocardiomyocytesviapreservingh3k27methylationandreducingferroptosis
AT huxiaolin gskj4aspecifichistonelysinedemethylase6ainhibitorameliorateslipotoxicitytocardiomyocytesviapreservingh3k27methylationandreducingferroptosis
AT chenling gskj4aspecifichistonelysinedemethylase6ainhibitorameliorateslipotoxicitytocardiomyocytesviapreservingh3k27methylationandreducingferroptosis
AT hangweijian gskj4aspecifichistonelysinedemethylase6ainhibitorameliorateslipotoxicitytocardiomyocytesviapreservingh3k27methylationandreducingferroptosis
AT chenjuan gskj4aspecifichistonelysinedemethylase6ainhibitorameliorateslipotoxicitytocardiomyocytesviapreservingh3k27methylationandreducingferroptosis